Article
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Neuro-oncology - 1 Aug 2022
Cantor Evan, Wierzbicki Kyle, Tarapore Rohinton S, Ravi Karthik, Thomas Chase, Cartaxo Rodrigo, Nand Yadav Viveka, Ravindran Ramya, Bruzek Amy K, Wadden Jack, John Vishal, May Babila Clarissa, Cummings Jessica R, Rahman Kawakibi Abed, Ji Sunjong, Ramos Johanna, Paul Alyssa, Walling Dustin, Leonard Marcia, Robertson Patricia, Franson Andrea, Mody Rajen, Garton Hugh J L, Venneti Sriram, Odia Yazmin, Kline Cassie, Vitanza Nicholas A, Khatua Soumen, Mueller Sabine, Allen Joshua E, Gardner Sharon L, Koschmann Carl
Abstract excerpt
BACKGROUND: Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, with patients rarely surviving 2 years from diagnosis. METHODS: We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). Patients enrolled on Arm D of the trial (n = 24) underwent serial lumbar puncture for cell-free tumor DNA (cf-tDNA) analysis and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.